11.02.16
Revlon has made a $1 million donation to the Revlon/UCLA Women’s Cancer Research Program. The donation was made by Revlon Chairman Ronald O. Perelman and Revlon CEO Fabian Garcia at their annual philanthropic luncheon in support of the Revlon’s Women Health Mission in Los Angeles. This donation brings Revlon’s total contribution to the program to over $50 million, and its cumulative commitment to more than $150 million.
The luncheon honored Dr. Dennis J. Slamon, MD, PhD, and Director of the Revlon/UCLA Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center.
“Over the past 25 years, I am proud to say that Dr. Slamon and the Revlon Women’s Cancer Program have developed therapeutics which are now suitable to target and treat over 80% of breast cancers,” said Perelman. “Only last year, the FDA designated Dr. Slamon’s latest development, Ibrance, ‘a breakthrough therapy,’ and fast-tracked its release to start saving the lives of women. This drug alone has the power to help over 60% of women affected by breast cancer.”
The luncheon honored Dr. Dennis J. Slamon, MD, PhD, and Director of the Revlon/UCLA Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center.
“Over the past 25 years, I am proud to say that Dr. Slamon and the Revlon Women’s Cancer Program have developed therapeutics which are now suitable to target and treat over 80% of breast cancers,” said Perelman. “Only last year, the FDA designated Dr. Slamon’s latest development, Ibrance, ‘a breakthrough therapy,’ and fast-tracked its release to start saving the lives of women. This drug alone has the power to help over 60% of women affected by breast cancer.”